Response to Comments: MolDX: Melanoma Risk Stratification Molecular Testing

This document (A58507) is a response to public comments on MolDX LCD L37750 and records a title change to 'MolDX: Melanoma Risk Stratification Molecular Testing' with a notice period beginning 2020-10-22 and effective date 2020-12-06. It does not itself specify clinical coverage criteria, limitations, or frequency limits; reviewers should consult LCD L37750 for the detailed coverage policy.

"This document is a response to provider comments on MolDX LCD L37750 (DecisionDX-Melanoma), noting the LCD title was revised to 'MolDX: Melanoma Risk Stratification Molecular Testing' and providing..."

Sign up to see full coverage criteria, indications, and limitations.